KR20120129893A - 고령자에 보호 면역을 제공하기 위한 방법 및 조성물 - Google Patents

고령자에 보호 면역을 제공하기 위한 방법 및 조성물 Download PDF

Info

Publication number
KR20120129893A
KR20120129893A KR1020127019714A KR20127019714A KR20120129893A KR 20120129893 A KR20120129893 A KR 20120129893A KR 1020127019714 A KR1020127019714 A KR 1020127019714A KR 20127019714 A KR20127019714 A KR 20127019714A KR 20120129893 A KR20120129893 A KR 20120129893A
Authority
KR
South Korea
Prior art keywords
dose
ala
ser
antigen
asn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127019714A
Other languages
English (en)
Korean (ko)
Inventor
엔. 데이비드 테일러
로버트 에스. 베커
알란 알. 쇼
린다 쥐. 터시
Original Assignee
백시네이트 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 백시네이트 코포레이션 filed Critical 백시네이트 코포레이션
Publication of KR20120129893A publication Critical patent/KR20120129893A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6068Other bacterial proteins, e.g. OMP
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020127019714A 2010-01-06 2011-01-05 고령자에 보호 면역을 제공하기 위한 방법 및 조성물 Ceased KR20120129893A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29259310P 2010-01-06 2010-01-06
US61/292,593 2010-01-06
PCT/US2011/020159 WO2011084967A2 (en) 2010-01-06 2011-01-05 Methods and compositions for providing protective immunity in the elderly

Publications (1)

Publication Number Publication Date
KR20120129893A true KR20120129893A (ko) 2012-11-28

Family

ID=44306116

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127019714A Ceased KR20120129893A (ko) 2010-01-06 2011-01-05 고령자에 보호 면역을 제공하기 위한 방법 및 조성물

Country Status (11)

Country Link
US (1) US20130095130A1 (enExample)
EP (1) EP2521563B1 (enExample)
JP (1) JP2013516469A (enExample)
KR (1) KR20120129893A (enExample)
CN (1) CN102740872A (enExample)
AU (1) AU2011203740B2 (enExample)
CA (1) CA2786306A1 (enExample)
MX (1) MX2012007916A (enExample)
SG (1) SG182305A1 (enExample)
WO (1) WO2011084967A2 (enExample)
ZA (1) ZA201205273B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008527009A (ja) 2005-01-19 2008-07-24 バクシネート コーポレーション 病原体関連分子パターンおよび抗原を含む組成物ならびに免疫応答を刺激するためのそれらの使用
EP2476432B1 (en) 2006-03-07 2015-08-19 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
SG190562A1 (en) 2008-04-18 2013-06-28 Vaxinnate Corp Deletion mutants of flagellin and methods of use
US8932598B2 (en) * 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976552A (en) * 1995-04-28 1999-11-02 Protein Sciences Corporation Virus vaccines
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
EP1827489B1 (en) * 2004-12-16 2012-10-31 Wake Forest University Health Sciences Use of flagellin in tumor immunotherapy
JP2008524261A (ja) * 2004-12-21 2008-07-10 バクシネート コーポレーション インフルエンザウイルスタンパク質の組成物およびその使用方法
US20090162400A1 (en) * 2004-12-21 2009-06-25 Powell Thomas J Compositions of influenza viral proteins and methods of use thereof
CA2596079A1 (en) * 2005-01-31 2006-08-10 Vaxinnate Corporation Novel polypeptide ligands for toll-like receptor 2 (tlr2)
EP1863529A1 (en) * 2005-03-23 2007-12-12 GlaxoSmithKline Biologicals S.A. Novel composition
EP2476432B1 (en) * 2006-03-07 2015-08-19 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
SG190562A1 (en) * 2008-04-18 2013-06-28 Vaxinnate Corp Deletion mutants of flagellin and methods of use
WO2009130618A2 (en) * 2008-04-25 2009-10-29 Institute For Systems Biology Flagellin polypeptide vaccines

Also Published As

Publication number Publication date
WO2011084967A3 (en) 2011-11-10
WO2011084967A2 (en) 2011-07-14
AU2011203740B2 (en) 2014-11-13
CN102740872A (zh) 2012-10-17
ZA201205273B (en) 2013-09-25
AU2011203740A1 (en) 2012-07-19
CA2786306A1 (en) 2011-07-14
EP2521563A2 (en) 2012-11-14
EP2521563A4 (en) 2013-07-24
MX2012007916A (es) 2012-11-06
SG182305A1 (en) 2012-08-30
US20130095130A1 (en) 2013-04-18
EP2521563B1 (en) 2016-12-07
JP2013516469A (ja) 2013-05-13

Similar Documents

Publication Publication Date Title
JP7250878B2 (ja) 新規多価ナノ粒子に基づくワクチン
ES2858315T3 (es) Proteína F de prefusión de VRS soluble estabilizada para uso en la profilaxis de la infección por VRS
AU2018200962B2 (en) Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
EP3494989B1 (en) Composite antigenic sequences and vaccines
KR102885621B1 (ko) 미생물 감염을 치료 및 예방하기 위한 면역원성 조성물
US20200268874A1 (en) Methods of Treating and Preventing Infections
Qiao et al. A self-assembling nanoparticle vaccine targeting the conserved epitope of influenza virus hemagglutinin stem elicits a cross-protective immune response
KR20120129893A (ko) 고령자에 보호 면역을 제공하기 위한 방법 및 조성물
JP2005170945A (ja) インフルエンザ血球凝集素多価ワクチンの製造方法
RU2757013C2 (ru) Рекомбинантная противогриппозная вакцина с широким спектром защиты и способ ее получения
WO2020034048A2 (es) Vacuna contra el síndrome cardiopulmonar causado por hantavirus
KR20250046320A (ko) 계절성 및 신종 감염의 치료 및 예방을 위한 백신
WO2024186901A2 (en) Broadly reactive immunogens of influenza h3 virus, compositions and methods of use thereof
JP2007314538A (ja) インフルエンザ血球凝集素多価ワクチンの製造方法
HK1203523B (en) Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
BR112016007868B1 (pt) Nanopartícula, seu uso, proteína de fusão, molécula de ácido nucleico, vacina contra o vírus do epstein-barr e método para a sua produção

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120725

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20151215

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170317

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170525

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170317

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I